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osting by EAbstract Malaria constitutes persistent threat to the human health and remains a distinct cause of
morbidity and mortality, 40% of the world population is at risk of exposure to this menace in 100
countries (WHO, 2001). Present data represents the registered cases of malaria in the hospitals and
clinics in India. Plasmodium vivax and Plasmodium falciparum infections were recorded 63.86%,
66.06%, 62.58% and 36.13%, 33.93%, 37.41%, respectively, amongst individuals with symptoms
of intermittent high fever for three days. Maximum transmission with highest slide positivity rates
(SPR) 61.76% and 50.14% was periodically and strategically observed during September and Octo-
ber while lowest yearly transmission slide positivity rates (SPR) (19.60–24.07%) was estimated in
the months of March and April. Average relapse rates (ARR) inP. vivax was recorded 17.1%. Short
term relapses were more recurring than the long term in the ratio of 4:1. Eighty-eight patients who
were administered with total of 1500 mg chloroquine and 75 mg primaquine through divided doses
also showed relapse rate of 4.5%. Patients suffering from falciparum malaria showed resistance
against chloroquine in 10.6% cases after getting 1500 mg chloroquine based on divided doses
(i.e. 600 mg on day 1 and 300 mg after 8 h and followed by 300 mg daily for 2 days.)
ª 2009 King Saud University. All rights reserved.1. Introduction
Malaria is a major burden for most resource-poor nations of
the world. Between 200 and 500 million deaths attributable
to malaria, most among the children of sub-Saharan Africa
(Breman, 2001). In fact, 9 out of 10 cases of malaria occur
in this region, while two third of remaining are concentrated.S. Al-Khalifa).
ity. All rights reserved. Peer-
d University.
lsevierin just six countries viz., India, Brazil, Sri Lanka, Vietnam,
Cambodia and Solomon Island. The goal of eradicating malar-
ia, once thought to be possible, was abandoned decades ago,
and the present goal of malaria control is ﬁrst to retard the
accelerating rates of disease and death and then to ‘‘Roll Back
Malaria’’.
In 1990s malaria re-emerged and took the lives of several
thousand people (Sharma, 1996). Factors responsible for the
re-emergence of malaria were vector resistance to insecticide
and parasite’s resistance to drug. In India 60–65% of the ma-
laria infections are reported to be due to Plasmodium vivax and
30–35% due to Plasmodium falciparum (Adak et al. 1998). The
worsening problems of drug resistance in many parts of the
world and the limited number of antimalarial drugs available
has increased difﬁculties for the development of anti-malarial
drug policies and the provision of adequate disease manage-
ment. It is now recognized that most endemic countries will
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malarial drugs used to treat uncomplicated malaria.
In India resistance of P. falciparum to chloroquine, the
cheapest and the most frequently used therapeutic drug was
ﬁrst reported in the year 1973 from Diphu of Karbi-Analog
district in Assam state. The reports on the resistance of P. fal-
ciparum to chloroquine and amodiaquine, ﬁrst observed in
1960–1961 in Colombia and in Brazil (Bruce-Chwatt, 1985),
were of greater consequence, since together with quinine these
are the most valuable drugs for the treatment of acute malaria.
Further reports on drug resistance came from Thailand,
Malaysia, Cambodia, Phillipines, Indonesia, Vietnam, Laos,
Burma and other areas of South-East Asia. Available informa-
tion indicates that P. falciparum has given rise to formidable
drug resistant strain in Asia. The problem of chloroquine
resistance in P. falciparum is widespread and now it is leading
towards multiple drug resistance against all major antimalari-
als (WHO, 1996).2. Materials and methods
Present study is based on the malaria cases enrolled in Jaw-
aharlal Nehru Medical College and a few other hospitals and
clinics of Aligarh during the years 2001, 2002 and 2003. Blood
smear were prepared from patients who attended hospitals and
clinics, complained for fever and headache and were suspected
of malaria. Thin and thick blood smears of patients were pre-
pared by ﬁnger prick, stained with J.S.B. and Giemsa stains
and microscopically examined under an oil immersion lens to
see the positivity for malaria infection. From malaria positive
cases, monthly prevalence of P. vivax and P. falciparum infec-
tions were recorded. Month-wise slide positivity rates (SPR)
and slide falciparum rates (SFR) were worked out for the years
2001, 2002 and 2003. Resistant and relapse cases were also
observed in P. falciparum and P. vivax infections, respectively.
For the study of relapse in P. vivax, one group of patients
was treated by giving 1500 mg chloroquine base in divided
doses (i.e. 600 mg on day 1 and 300 mg after 8 h followed by
300 mg daily for 2 days). The dose of child was adjusted
according to his/her body weight. While patients in other
group were administered 1500 mg chloroquine in the similar
manner followed by 15 mg primaquine daily for 5 days and
then followed up carefully. To determine the pattern of relapse
in P. vivax each patient was identiﬁed individually by name,
address and subsequent treatment. On reporting back blood
smears were prepared from the patient and examined micro-
scopically for the presence of malaria parasite and entered
against his/her name.
The following criteria were used in classifying the patients
into primary cases and non-relapse and relapse categories in
the present study. Patient reporting for the ﬁrst time (having
no history of malaria) with acute illness and showing symp-
toms such as high fever, severe headache, loss of appetite,
occasional vomiting and microscopic evidence of P. vivax
infection were considered as primary cases. Some patients in
this group who had no clinical symptoms of malaria or para-
sitological evidence of P. vivax infection following their pri-
mary infection during the entire period was considered as
non-relapse cases. Those patients who reported back to the
clinic within one month to one year with renewed clinical
symptom (mild) along with a periodic alternate day fever(not observed in the primary cases) and found to be micro-
scopically positive for P. vivax infection were considered as re-
lapse cases. After medication if patient again suffered from
malaria within 3 months with more regular paroxysm, he/she
was treated as a case of short term relapse. But if it happened
beyond 3 months then the case was considered as long term re-
lapse. Cases of P. vivax who did not respond to 1500 mg of
chloroquine and 75 mg primaquine was recorded as chloro-
quine resistant cases.
2.1. Drug resistance in P. falciparum infections
For drug resistance, patients who were positive for P. falcipa-
rum infections were given 1500 mg chloroquine base in divided
doses (i.e. 600 mg on day 0, 300 mg after 8 h followed by
300 mg daily for 2 days). The dose of child was adjusted
according to his/her body weight. Blood ﬁlms of those patients
who reported back with fever within 4 weeks of treatment were
examined for P. falciparum infection. If found positive, such
cases were recorded as chloroquine resistant cases. Level of
resistance (i.e. RI, RII, RIII) was ascertained on the basis of
late and early recrudescence.3. Results
Tables 1–3 show month wise slide positivity rates and slide fal-
ciparum rates for the years 2001–2003 for P. vivax and P. fal-
ciparum infections observed in Aligarh. These tables also
provide information on seasonal ﬂuctuations of aforesaid spe-
cies. P. vivax infection was predominant and was recorded in
all months of the year, with almost similar seasonal patterns
during the three successive years. P. vivax showed a gradual
increasing trend from July onwards reaching a peak in Septem-
ber soon after the rainy season, and then showed a decline in
December which continued until June. P. falciparum infections
started gradual increasing in July–August and showed a peak
in September and October and then decline November on-
wards with the on set of winter and continued to decline till
June.
During 2001 out of 1473 slides examined, 487 were found
positive for malaria of which 311 belonged to P. vivax and
176 to P. falciparum. In 2002 a total of 1369 slides were exam-
ined, out of which 498 were found positive for malaria of
which 329 belonged to P. vivax and 169 to P. falciparum. In
2003 a total of 1428 slides were examined for malaria infection,
out of which 580 were found positive. Slides showing positivity
for P. vivax and P. falciparum were 363 and 217, respectively.
During 2001–2003 overall percentage of P. vivax and P. falci-
parum were 63.86%, 66.06%, 62.58% and 36.13%, 33.93%
and 37.41%, respectively (Table 4).
It was observed that malaria transmission was least from
January to April. During the months of May, June and July
transmission was low with slight ﬂuctuating ﬁgures for the
years 2001–2003 which was in accordance with the commence-
ment of pre-monsoon shower that contributed slightly in-
creased or decreased transmission rate in proceeding months.
Increased rate of transmission was recorded July onwards,
reaching a peak soon after rains in September and October fol-
lowed by a sharp decline to a low level in December. During
peak transmission season mean temperature and relative
humidity ranged somewhere around 26–28 C and 77–88%.
Table 1 Prevalence of malaria showing parasite distribution, SPR and SFR during year 2001.
Month BSE Total cases P. vivax P. falciparum SPR SFR
Jan 27 8 6 2 29.62 7.40
Feb 32 8 5 3 25.00 9.35
March 47 11 7 4 23.40 8.51
Apr 54 13 8 5 24.07 9.25
May 62 12 8 4 19.35 6.45
June 55 11 7 4 20.00 7.27
July 74 27 21 6 36.48 8.10
Aug 135 28 19 9 20.74 6.66
Sept 382 170 108 62 44.50 16.23
Oct 351 129 78 51 36.75 14.52
Nov 157 50 32 18 31.84 11.46
Dec 97 20 12 8 20.61 8.24
Table 2 Prevalence of malaria showing parasite distribution, SPR and SFR during year 2002.
Month BSE Total cases P. vivax P. falciparum SPR SFR
Jan 41 11 8 3 26.95 7.31
Feb 53 13 9 4 24.52 7.54
Mar 39 11 9 2 28.20 5.12
Apr 65 12 8 4 18.46 6.15
May 47 12 9 3 25.53 6.38
June 67 17 11 6 25.37 8.95
July 89 28 21 7 31.46 7.86
Aug 143 44 31 13 30.76 9.09
Sept 247 136 94 42 55.06 17.00
Oct 293 138 81 57 47.09 19.45
Nov 182 62 41 21 34.06 11.53
Dec 103 14 7 7 13.59 6.79
Table 3 Prevalence of malaria showing parasite distribution, SPR and SFR during year 2003.
Month BSE Total cases P. vivax P. falciparum SPR SFR
Jan 37 8 6 2 21.62 5.40
Feb 31 11 9 2 35.48 6.45
Mar 51 10 7 3 19.60 5.88
Apr 72 16 11 5 22.2 6.94
May 61 14 10 4 22.95 6.55
June 57 12 9 3 21.05 5.26
July 95 21 14 7 22.10 7.36
Aug 149 53 39 14 35.5 9.39
Sept 218 134 92 42 61.46 19.26
Oct 347 174 102 72 50.14 20.17
Nov 213 106 55 51 49.76 23.94
Dec 97 21 9 12 21.64 12.37
Table 4 Prevalence of malaria P. vivax and P. falciparum infections during 2001–2003.
Years BSE Total positive cases P. vivax P. falciparum
2001 1473 487 311(63.86%) 176(36.13%)
2002 1369 498 329(66.06%) 169(33.93%)
2003 1428 580 363(62.58%) 217(37.41%)
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versus relapsing patients and relapse rates with different follow
up duration. In 2001 a total of 144 patients were observed ofwhich 122 did not have any further relapse whereas 22 had re-
lapses in two year follow up study having a relapse rate of
15.2%. Similarly for the year 2002 and 2003 the relapse rates
Table 5 Relapse cases in P. vivax infection.
Years Total no. of
patients observed
Non-relapsing
patients
Relapsing
patients
Short term
relapse
Long term
relapse
Relapse
rate
Follow
-up year
2001 144 122 22 16 6 15.2 2
2002 178 144 34 28 6 19.1 2
2003 204 169 35 27 8 17.1 1
2003 88a 84 4 4 – 4.5 1
a Patients given 75 mg primaquine base following chloroquine treatment.
Table 6 Chloroquine resistant cases in P. falciparum infection.
Years No. of P. falciparum
patients observed
Non-resistant
patients
Resistant patients Resistance rate
Total RI RII RIII Total RI RII RIII
2001 124 112 12 8 4 – 9.6 6.45 3.2 –
16 10 6 – 10.8 6.75 4 –
2003 157 139 18 13 5 – 11.4 8.2 3.2 –
34 M.A. Saiﬁ et al.were 19.1% and 17.1%, respectively. Short term relapses were
more then the long term in the ratio of about 4:1. In 2001–2003
short and long term relapses were recorded as 11.1% and
4.1%, 15.7% and 3.3% and 13.2% and 3.92%, respectively.
Above percentage of relapse were recorded in patients who
were given 1500 mg chloroquine base in divided doses (i.e.
600 mg on day 1 and 300 mg after 8 h followed by 300 mg dai-
ly for 2 days). Eighty-eight patients who were administered
with 1500 mg chloroquine and 75 mg primaquine in divided
doses also showed resistance in 4.5% cases.
Table 6 shows the frequency distributions of 124,148 and
157 patients showing resistance against chloroquine in 9.6%,
10.8% and 11.4% cases after getting 1500 mg chloroquine base
in divided doses (i.e. 600 mg on day 1 and 300 mg after 8 h fol-
lowed by 300 mg daily for 2 days). Out of 124 patients studied
during 2001, 112 were susceptible, whereas 12 patients showed
resistance against chloroquine. The level of resistance was RI
and RII type in 6.4% and 3.2% cases. In 2002 out of 148 pa-
tients 132 were susceptible while 16 showed resistance out of
which 6.7% were of RI type and 4.1% were of RII type. Sim-
ilarly in the year 2003 out of 157 patients observed 139 were
found susceptible and 18 showed resistance out of which
8.2% were of RI type and 3.2% were of RII type.4. Discussion
Blood smears of patients attending hospitals and clinics of Ali-
garh showing symptoms such as high fever, severe headache,
loss of appetite and occasional vomiting were examined micro-
scopically for P. vivax and P. falciparum infections. Resistant
and relapse cases were observed and followed up in P. falcipa-
rum and P. vivax infections, respectively.
In the present study peak transmission of malaria during
the months of September and October which was recorded
high during the years 2001–2003 was probably because of
the availability of plenty of water bodies, supporting breeding
of vector species after rainy season in preceding months. Mod-
erate temperature (i.e. 26–28 C) and optimum humidity (i.e.
77–88%) during these months which were ideal for the mos-
quito breeding might have inﬂuenced increase in vector popu-
lation which must have contributed to maximum transmissionas earlier observed by Adak et al. (1998) in Delhi. Increased
transmission of malaria was also recorded during peak season
in Assam in areas having streams where vector species which
happens to be Anopheles minimus was in abundance (Wajihul-
lah et al. 1992). Whereas least transmission which was re-
corded from December to June in the present study was
because of adverse environmental factors which caused reduc-
tion in number of vector species. During these months either
extreme dry cold or dry heat conditions prevail which affect
vectors adversely either by making water bodies unsuitable
or very slow for the breeding or by making them scarce as a
result of high temperature which even kill the vector.
Percentage for P. vivax during years 2001–2003 was 63.44,
66.06 and 62.58 while for P. falciparum it was 36.55, 33.93 and
37.41. This indicates decrease in P. vivax and an increase in
P. falciparum infection. Development of resistance against rou-
tine curative drug (i.e. chloroquine) might have been one of the
reasons for this increase in P. falciparum. Slide falciparum rate
(SFR) was considerably high during peak transmission period
as well as in colder months even when transmission rate is low.
It is difﬁcult to draw exact conclusion but it seems that devel-
opment of P. falciparum is supported by the vector species
more readily as compared to P. vivax, may be it is a particular
strain of some vector species which emerges in good number in
winters and contributed for raised falciparummalaria. Another
probable explanation may be this that complicated cases are
generally referred to medical college and a few of them hap-
pens to be falciparum malaria, might have contributed to raise
number of cases. Since we have collected maximum cases from
medical college, SFR obtained in the present study is bit high.
In contrast P. vivax cases are generally treated outside easily
cured and therefore are not on record, hence its transmission
rate, which is observed during this study is proportionately
low.
Relapse rate in P. vivax during the year 2001–2003 follow-
ing the administration of 1500 mg chloroquine base were
15.2%, 19.1% and 17.1%, respectively. Short-term relapses
were more as compared to the long term relapses, which were
11.1%, 15.7%, 13.23% and 4.1%, 3.3%, 3.92%. But relapse
rate was quite low (i.e. 4.5%) and was of short term type, when
75 mg primaquine base was also administered following chlo-
roquine treatment. This indicates that both chloroquine and
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administered in a total curative dose to the patients suffering
from vivax malaria. Similar observations were made by Sri-
vastava et al. (1996) who recorded more short-term relapses
and a few long-term relapses after administration of 600 mg
chloroquine, is in accordance of our ﬁnding where more
short-term relapses recorded. Adak et al. (1998) recorded 23–
44% relapsing cases within a period of 5 years study after giv-
ing 900 mg chloroquine in two doses (600 + 300 mg). Smoak
et al. (1997) observed relapses in 43% Somalian soldiers who
received standard dose of primaquine. In these studies relapse
rates were high as compared to our ﬁndings. It may be because
of the reason that anti relapse drug, primaquine was not
administered by Adak et al. while in case of Smoak
et al.(1997) study, may be strain of P. vivax was more tolerant
to anti relapse drug, primaquine and did not respond to it in a
fairly good number of cases.
In the present study 9.6%, 10.8% and 11.4% patients suf-
fering from falciparum malaria showed resistance by showing
recrudescence around ﬁrst and second week following chloro-
quine treatment during 2001–2003. Sharma (1999) reported
30% resistant cases in high transmission zone in India. Many
other reports are available in India and abroad which show
increasing trend of drug resistance. Ghosh et al. (1992) ob-
served 25% chloroquine resistant cases in Orissa. Shah et al.
(1997) reported chloroquine resistant cases in Pakistan and
Afghanistan. Mharakurwas et al. (1997) reported resistance
in as much as 52% patients following chloroquine treatment.
Bojang et al. (1998) reported failure of chloroquine in Gam-
bian children. In present study less percentage of resistant
cases were recorded which might be because of the reason that
study was conducted in low transmission region where P. fal-
ciparum infection is proportionately less.
Regarding the interpretation of the results, one may dis-
agree with the differentiation of primary attack versus relapse
or reinfection, particularly during peak transmission season.
However, in the absence of any clinical or parasitological mar-
ker, the following observations are considered as relevant. In
the present study, malaria cases detected between December
and June (the supposed non-transmission season) could be
grouped in three categories.
(I) Infections acquired in the previous transmission season
i.e. between July and November but remained unde-
tected and thus untreated.
(II) Infections acquired during the previous transmission
season that were detected, treated and subsequently
reappeared (relapse).
(III) Infections acquired during the previous transmission
season that become clinically and parasitologically posi-
tive after a prolonged period (delayed primary attack).
Although the reinfection, particularly during the main
transmission season could not be ruled out, real transmission
from December to June is probably occasional and at a very
low level, if supposed non-transmission period with a deﬁnite
history of malaria were considered to be relapse rather than
reinfections, whereas those detected with a history of malaria
were considered delayed primary attacks. However, some
uncertainty still exists regarding the possibility of reinfection
during the supposed non transmission season, which probably
will persist until some diagnostic tool is developed that can dis-tinguish the primary attack and subsequent relapse from
reinfection.
It is quite evident from the duration of follow up study (1–2
years) that the average resistance rate for the year 2001 was
9.6, 2002 was 10.8 and for the year 2003 was 11.4. The relapse
rates for the years 2001–2003 were 15.2, 19.1 and 17.1, respec-
tively. Therefore the present drug policy of National Malaria
Eradication Programme for the administration of chloroquine
in P. falciparum as the ﬁrst line curative drug and primaquine
15 mg of base, once a day for ﬁve consecutive days as anti re-
lapse drug for the radical cure of P. vivax infection warrants its
reconsideration.
In the view of this information, it is suggested that the fre-
quency distribution/ratios of different parasite forms responsi-
ble for different relapse patterns should be determined in
different P. vivax ecosystems with reference to space and time,
which are probably not constant and likely to be time depen-
dent. In addition, the degree to which these parasites variants
interact with each other will no doubt have an impact on the
maintenance of genetic diversity and regulation of the parasite
population as a whole. However, in the absence of parasitolog-
ical and clinical markers, it may be difﬁcult to characterize these
forms; perhaps ampliﬁcation of speciﬁc DNA sequences by the
polymerase chain reaction using speciﬁc oligonucleotide probes
from different parasites isolates of relapsing and non-relapsing
patients could be used to analyse the genetic diversity of the
P. vivax population and correlate this with epidemiological
ﬁndings. Therefore there is a strong need for integrated labora-
tory and ﬁelds studies as well as the use of mathematical models
to interpret the complex transmission dynamics of P. vivax and
P. falciparum so that appropriate malaria control strategies,
including chemotherapeutic measures can be devised to prevent
relapse and resistance problems in P. vivax and P. falciparum.References
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